Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity [Phase 2]
A Phase 2 clinical trial update exploring belinostat pharmacokinetics and toxicity guided by UGT1A1 genotype in neuroendocrine tumors.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors [Phase 1, Phase 2]
Perspective Therapeutics is recruiting for a Phase 1/Phase 2 study of targeted alpha-particle therapy for advanced SSTR2-positive neuroendoc…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
The document provides an update to the follow-up protocol for subjects previously enrolled in NCI Surgery Branch studies. It covers follow-u…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors [Phase 2]
This entry describes a Phase 2 clinical trial on the natural history and management of Von Hippel-Lindau–associated pancreatic neuroendocrin…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
This clinical trial update reports a retrospective cohort analysis examining the optimal sequence of surufatinib and somatostatin analog the…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors [Phase 1]
A Phase 1 trial is evaluating the combination of cabozantinib with Lutetium-177 DOTATATE in neuroendocrine tumors expressing somatostatin re…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. [Phase 1]
This is a Phase 1 clinical trial update for RayzeBio's RYZ401 in subjects with solid tumors expressing somatostatin receptors; the study is …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors [Phase 2]
This is a Phase 2 clinical trial update evaluating whether adding Triapine to Lutetium-177 dotatate improves outcomes for metastatic neuroen…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake [Phase 2]
This ClinicalTrials.gov update details a Phase 2 study evaluating ultralow-dose PET imaging of SSTR2 radiotracer uptake, with participants i…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating lutetium Lu-177 dotatate (Lutathera) in combination with olaparib for inoperable gastroenteropancre…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Ipsen-sponsored clinical trial evaluating cabozantinib in participants with neuroendocrine tumors who have received prior treatment is curre…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy [Phase 3]
Phase 3 trial update for RYZ101 versus standard of care in patients with inoperable, well-differentiated SSTR-positive gastroenteropancreati…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors [Phase 1]
First-in-human Phase 1 trial update of the antibody-drug conjugate ADCT-701 in patients with neuroendocrine tumors, neuroendocrine carcinoma…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors [Phase 1]
A Phase 1 trial evaluating donor natural killer cells with cyclophosphamide and etoposide in children and young adults with relapsed or refr…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms [Phase 2]
Phase 2 clinical trial update for tarlatamab in DLL3-expressing tumors, including neuroendocrine neoplasms.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Using Novel Imaging to More Safely Treat Neuroendocrine Tumors [Phase 1]
Phase 1 trial at University of Wisconsin–Madison evaluating novel imaging to treat neuroendocrine tumors; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas [Phase 2]
A Phase 2 clinical trial evaluating temozolomide plus SurVaxM (survivin long peptide vaccine) for progressing metastatic neuroendocrine carc…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial to evaluate safety and preliminary effectiveness of CRN09682 in SST2-expressing neuroendocrine neoplasms and othe…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
A pilot study evaluating total-body PET imaging with FDA-approved radiotracers beyond 18F-FDG to image cancer. It aims to assess feasibility…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
This clinical trial update outlines efforts to define standardized PET imaging response criteria for people with neuroendocrine tumors.
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: DLL3-Targeted PET/CT in Neuroendocrine Carcinoma [NA]
A DLL3-targeted PET/CT imaging trial for DLL3-expressing neuroendocrine tumors is currently recruiting at The First Affiliated Hospital of X…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. [Phase 3]
A Phase 3 trial is comparing radiotherapy to everolimus for somatostatin receptor-positive neuroendocrine tumors of the lung and thymus, and…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
Clinical trial update from University Health Network, Toronto evaluating the risk of myelodysplastic syndrome and acute myeloid leukemia in …
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer [Phase 2]
A Phase 2 clinical trial is evaluating tumor-infiltrating lymphocyte immunotherapy for multiple metastatic cancers and is currently recruiti…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: CardioNETPOL National Registry of Carcinoid Heart Disease
This entry describes the CardioNETPOL national registry for carcinoid heart disease, collecting data on patients with carcinoid heart diseas…